These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20589701)

  • 1. Acquired factor VIII inhibitor in Sjögren's syndrome.
    Vintimilla M; Joseph A; Ranganathan P
    Arthritis Care Res (Hoboken); 2010 Jul; 62(7):1047-50. PubMed ID: 20589701
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
    Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
    Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T
    Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract]   [Full Text] [Related]  

  • 4. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 5. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
    Atzeni F; Sarzi-Puttini P
    Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome.
    Sánchez-Cano D; Callejas-Rubio JL; Lara-Jiménez MA; López-Trascasa M; Circadi M; Ortego-Centeno N
    Lupus; 2008 Mar; 17(3):228-9. PubMed ID: 18372365
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab.
    Ahmadi-Simab K; Lamprecht P; Nölle B; Ai M; Gross WL
    Ann Rheum Dis; 2005 Jul; 64(7):1087-8. PubMed ID: 15958765
    [No Abstract]   [Full Text] [Related]  

  • 8. Latest update on the primary Sjögren's syndrome.
    Youinou P; Pers JO
    Presse Med; 2012 Sep; 41(9 Pt 2):e437-9. PubMed ID: 22857888
    [No Abstract]   [Full Text] [Related]  

  • 9. Sjogren's syndrome. When your tissues dry out.
    Mayo Clin Health Lett; 2006 Jul; 24(7):7. PubMed ID: 16865802
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.
    Somer BG; Tsai DE; Downs L; Weinstein B; Schuster SJ;
    Arthritis Rheum; 2003 Jun; 49(3):394-8. PubMed ID: 12794796
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sjogren's syndrome and pseudolymphoma.
    Deutsch HJ
    Ann Otol Rhinol Laryngol; 1967 Dec; 76(5):1074-84. PubMed ID: 6074240
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress and regression within primary Sjögren's syndrome.
    Manthorpe R; Bredberg A; Henriksson G; Larsson A
    Scand J Rheumatol; 2006; 35(1):1-6. PubMed ID: 16467033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
    Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG
    Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of refractory neuroSjogren with Rituximab.
    Yamout B; El-Hajj T; Barada W; Uthman I
    Lupus; 2007; 16(7):521-3. PubMed ID: 17670852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case of retroperitoneal fibrosis exhibiting a variety of auto- antibodies and complicated by Sjogren's syndrome].
    Sakamoto K; Ueda K; Kawabata T; Harada N; Kida Y; Nibu T; Furuie D; Haneda K; Yoshikawa R
    Nihon Naika Gakkai Zasshi; 1998 Nov; 87(11):2319-21. PubMed ID: 9921220
    [No Abstract]   [Full Text] [Related]  

  • 17. [Is rituximab a promising treatment for Sjögren's syndrome?].
    Devauchelle-Pensec V; Pers JO; Youinou P; Saraux A
    Rev Med Interne; 2008 Dec; 29(12):967-70. PubMed ID: 18403066
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon alfa treatment for Sjogren's syndrome associated neuropathy.
    Yamada S; Mori K; Matsuo K; Inukai A; Kawagashira Y; Sobue G
    J Neurol Neurosurg Psychiatry; 2005 Apr; 76(4):576-8. PubMed ID: 15774450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First experience with the application of rituximab for the treatment of patients with Sjogren's syndrome and disease].
    Vasil'ev VI; Logvinenko OA; Kokosadze NV; Gaĭduk IV; Varlamova EIu; Kovrigina AM; Gorodetskiĭ VR; Nasonov EL
    Vestn Ross Akad Med Nauk; 2009; (2):3-10. PubMed ID: 19283903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired factor VIII:C inhibitor in a patient with Sjögren's syndrome: successful treatment with steroid and immunosuppressive therapy.
    Dannhäuser D; Casonato A; Pietrogrande F; Pontara E; Bertomoro A; Zerbinati P; Girolami A
    Acta Haematol; 1994; 91(2):73-6. PubMed ID: 8023647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.